Smart nanosystems: Bio-inspired technologies that interact with the host environment

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 47, 2015, Pages 14460-14466

  Kwon, Ester J ^a   Lo, Justin H ^a,b,c   Bhatia, Sangeeta N ^a,b,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer nanotechnology; Environment responsive; Host priming; Nanosystems; Smart nanomaterials

Indexed keywords

CONFERENCE PAPER; ENZYME ASSAY; HOMEOSTASIS; HOST; MOLECULAR INTERACTION; NANOENGINEERING; NANOTECHNOLOGY; PH; PRIORITY JOURNAL; HUMAN; NANOMEDICINE; OXIDATION REDUCTION REACTION;

NANOPARTICLE;

HOMEOSTASIS; HUMANS; HYDROGEN-ION CONCENTRATION; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; OXIDATION-REDUCTION;

EID: 84948411384     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1508522112     Document Type: Article

References (67)

1. Anglin EJ, Cheng L, Freeman WR, Sailor MJ (2008) Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 60(11):1266-1277.
2. Weissleder R, et al. (1990) Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 175(2):489-493.
3. Wang F, Banerjee D, Liu Y, Chen X, Liu X (2010) Upconversion nanoparticles in biological labeling, imaging, and therapy. Analyst (Lond) 135(8):1839-1854.
4. Petros RA, De Simone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615-627.
5. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM (2015) A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 14(4):239-247.
6. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771-782.
7. Harisinghani MG, et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25):2491-2499.
8. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7(11):653-664.
9. Schrauwen EJA, Fouchier RAM (2014) Host adaptation and transmission of influenza A viruses in mammals. Emerg Microbes Infec 3, e9.
10. Ryser HJ, Levy EM, Mandel R, Di Sciullo GJ (1994) Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 91(10):4559-4563.
11. Singh N, Agrawal A, Leung AK, Sharp PA, Bhatia SN (2010) Effect of nanoparticle conjugation on gene silencing by RNA interference. J Am Chem Soc 132(24):8241-8243.
12. Wilson DS, et al. (2010) Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9(11):923-928.
13. Sowers MA, et al. (2014) Redox-responsive branched-bottlebrush polymers for in vivo MRI and fluorescence imaging. Nat Commun 5:5460.
14. Weinstain R, Savariar EN, Felsen CN, Tsien RY (2014) In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides. J Am Chem Soc 136(3):874-877.
15. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15(7):690-698.
16. Procko E, et al. (2014) A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell 157(7):1644-1656.
17. Berguig GY, et al. (2015) Intracellular delivery system for antibody-peptide drug conjugates. Molec Therap 23(5):907-917.
18. Sonaje K, et al. (2010) Self-assembled pH-sensitive nanoparticles: A platform for oral delivery of protein drugs. Adv Funct Mater 20(21):3695-3700.
19. Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 1(2):117-128.
20. Joshi-Barr S, De Gracia Lux C, Mahmoud E, Almutairi A (2014) Exploiting oxidative microenvironments in the body as triggers for drug delivery systems. Antioxid Redox Signal 21(5):730-754.
21. Martin GR, Jain RK (1994) Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 54(21):5670-5674.
22. Lynn DM, Amiji MM, Langer R (2001) pH-responsive polymer microspheres: Rapid release of encapsulated material within the range of intracellular pH. Angew Chem Int Ed Engl 40(9):1707-1710.
23. Shenoy D, Little S, Langer R, Amiji M (2005) Poly (ethylene oxide) - modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm 2(5):357-366.
24. Shenoy D, Little S, Langer R, Amiji M (2005) Poly (ethylene oxide) - modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharm Res 22(12):2107-2114.
25. Poon Z, Chang D, Zhao X, Hammond PT (2011) Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 5(6):4284-4292.
26. Dreaden EC, et al. (2014) Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles. ACS Nano 8(8):8374-8382.
27. López-Otín C, Hunter T (2010) The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 10(4):278-292.
28. Turk B (2006) Targeting proteases: Successes, failures and future prospects. Nat Rev Drug Discov 5(9):785-799.
29. Yu IM, et al. (2008) Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319(5871):1834-1837.
30. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17(4):375-378.
31. Law B, Curino A, Bugge TH, Weissleder R, Tung C-H (2004) Design, synthesis, and characterization of urokinase plasminogenactivator-sensitive near-infrared reporter. Chem Biol 11(1):99-106.
32. Chen J, et al. (2005) Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 111(14):1800-1805.
33. Jaffer FA, Libby P, Weissleder R (2009) Optical and multimodality molecular imaging: Insights into atherosclerosis. Arterioscler Thromb Vasc Biol 29(7):1017-1024.
34. Aikawa E, et al. (2007) Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115(3):377-386.
35. Kwong GA, et al. (2013) Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 31(1):63-70.
36. Lin KY, Kwong GA, Warren AD, Wood DK, Bhatia SN (2013) Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 7(10):9001-9009.
37. Warren AD, Kwong GA, Wood DK, Lin KY, Bhatia SN (2014) Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci USA 111(10):3671-3676.
38. Warren AD, et al. (2014) Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers. J Am Chem Soc 136(39):13709-13714.
39. Jiang T, et al. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101(51):17867-17872.
40. Olson ES, et al. (2009) In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol 1(5-6):382-393.
41. Olson ES, et al. (2012) In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol 4(6):595-605.
42. Harris TJ, et al. (2008) Protease-triggered unveiling of bioactive nanoparticles. Small 4(9):1307-1312.
43. Zhu L, Wang T, Perche F, Taigind A, Torchilin VP (2013) Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci USA 110(42):17047-17052.
44. Ye D, et al. (2014) Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem 6(6):519-526.
45. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 15(7):539-553.
46. Cryer PE, Davis SN, Shamoon H (2003) Hypoglycemia in diabetes. Diabetes Care 26(6):1902-1912.
47. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R (2015) Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov 14(1):45-57.
48. Gu Z, et al. (2013) Injectable nano-network for glucose-mediated insulin delivery. ACS Nano 7(5):4194-4201.
49. Gu Z, et al. (2013) Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. ACS Nano 7(8):6758-6766.
50. Chou DH, et al. (2015) Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc Natl Acad Sci USA 112(8):2401-2406.
51. Lin KY, Lo JH, Consul N, Kwong GA, Bhatia SN (2014) Self-titrating anticoagulant nanocomplexes that restore homeostatic regulation of the coagulation cascade. ACS Nano 8(9):8776-8785.
52. Bertram JP, et al. (2009) Intravenous hemostat: Nanotechnology to halt bleeding. Sci Transl Med 1(11):11ra22.
53. Chan LW, et al. (2015) A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis. Sci Transl Med 7(277):277ra29.
54. Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16(4):343-353.
55. Hallahan D, et al. (2003) Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3(1):63-74.
56. Han Z, et al. (2008) Noninvasive assessment of cancer response to therapy. Nat Med 14(3):343-349.
57. Lowery A, Onishko H, Hallahan DE, Han Z (2011) Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release 150(1):117-124.
58. Passarella RJ, et al. (2010) Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res 70(11):4550-4559.
59. Lin KY, Kwon EJ, Lo JH, Bhatia SN (2014) Drug-induced amplification of nanoparticle targeting to tumors. Nano Today 9(5):550-559.
60. Sengupta S, et al. (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050):568-572.
61. Chauhan VP, et al. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7(6):383-388.
62. Simberg D, et al. (2007) Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104(3):932-936.
63. Von Maltzahn G, et al. (2011) Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 10(7):545-552.
64. Hauert S, Bhatia SN (2014) Mechanisms of cooperation in cancer nanomedicine: Towards systems nanotechnology. Trends Biotechnol 32(9):448-455.
65. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
66. Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra39.
67. Mito JK, et al. (2012) Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer 118(21):5320-5330.